Abnormal cannabidiol

Abnormal cannabidiol (Abn-CBD) is a synthetic cannabinoid that behaves differently from typical cannabinoids. It was first synthesized and studied by a group of scientists led by Raphael Mechoulam, a pioneer in the field of cannabis research. Abn-CBD does not bind to the traditional cannabinoid receptors, CB1 and CB2, but it still produces biological effects, which has led to the discovery of novel cannabinoid receptors.

Chemistry

Abnormal cannabidiol is a synthetic compound, meaning it is not naturally occurring. It is a derivative of the more well-known cannabinoid, cannabidiol (CBD). The term "abnormal" refers to the unusual placement of the side chain, which is opposite to that in natural cannabinoids.

Pharmacology

Abn-CBD does not bind to the traditional cannabinoid receptors, CB1 and CB2. Instead, it acts on a novel cannabinoid receptor, currently known as the "abnormal cannabidiol receptor" or "Abn-CBD receptor". This receptor is thought to be a member of the G protein-coupled receptor (GPCR) family, but its exact identity is still under investigation.

Therapeutic potential

Research into Abn-CBD has suggested potential therapeutic uses. It has been shown to have vasodilatory effects, meaning it can widen blood vessels and improve blood flow. This could potentially be useful in treating conditions such as hypertension and atherosclerosis. However, more research is needed to fully understand the therapeutic potential of Abn-CBD.

See also

• Cannabinoid receptor
• Cannabidiol
• Raphael Mechoulam